 |
|
|
| |
Safety and Pharmacodynamics of Oral TLR-7 Agonist
GS-9620 in Patients With Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Edward J. Gane,1 Eric Sicard,2 Stuart C. Gordon,3 Daniel Gruener,4 Stuart K. Roberts,5 Suzanne Kim,6 Wendy Cheng,7 Carla S. Coffin,8 Richard Fedorak,9 Paul Y. Kwo,10 Barbara A. Leggett,11 Daryl Lau,12 Young-Suk Lim,13 Y.J. Kim,14 Stefan Pflanz,15 Benedetta Massetto,15 Mani Subramanian,15 John G. McHutchison,15 Bradley Freilich,16 Kumar Visvanathan17
1Auckland Clinical Studies, Auckland, New Zealand; 2Algorithme Pharma, Inc., Montreal, Quebec, Canada; 3Henry Ford Health Systems, Detroit, MI; 4CRI Worldwide, LLC, Philadelphia, PA; 5Alfred Hospital, Melbourne, Australia; 6West Coast Clinical Trials, LLC, Costa Mesa, CA;
7Royal Perth Hospital, Perth, Australia; 8University of Calgary, Alberta, Canada; 9University of Alberta Hospital, Edmonton, Canada; 10Indiana University, Indianapolis, IN; 11Royal Brisbane and Women's Hospital, Brisbane, Australia; 12Beth Israel Deaconess Medical Center, Boston, MA;
13Asan Medical Center, Seoul, South Korea; 14Seoul National University Hospital, Seoul; 15Gilead Sciences, Inc, Foster City, CA; 16Kansas City Research Institute, Kansas City, MO; 17Southern Health, Monash University and St. Vincent's Hospital, University of Melbourne, Australia
|
| |
|
|
|
|
|
